PURPOSE: The aim of the study was to assess the clinical activity and @entity137 of @entity901 and @entity4181 in combination with bolus and continuous infusional @entity1487 administered every 2  weeks (modified FOLFOX-6 regimen) to @entity1 with @entity420 of an unknown primary site (ACUP). METHODS: Previously untreated ACUP @entity1 were treated with @entity901 (100  mg/m(2)) and @entity4181 (200  mg/m(2)) as a 2-h infusion followed by bolus administration of @entity1487 (400  mg/m(2)) and continuous infusion of @entity1487 (2400  mg/m(2)) every 2  weeks. RESULTS: A total of 23 @entity1 were enrolled and treated with a modified FOLFOX-6 regimen between May 2009 and November 2014. This trial was terminated before the scheduled enrollment due to poor accrual. A total of 134 cycles of mFOLFOX-6 were administered to 23 @entity1 . The median number of cycles of mFOLFOX-6 was 5 (range 1-12). Among 20 @entity1 whose @entity5 responses were evaluable, seven @entity1 showed a partial response (no complete response), with an objective response rate of 35.0  %. The median duration of response was 3.9  months (range 3.0-19.8). The median progression-free survival and overall survival were 3.0 and 9.5  months, respectively (95  % confidence interval 1.4-6.7  months and 4.8-26.4  months, respectively). Treatment-related @entity137 was manageable. CONCLUSIONS: mFOLFOX-6 showed modest activity in treatment-na  ve @entity1 with ACUP. A future, prospective large-scale study incorporating a parallel molecular prediction marker study is warranted.

A phase II trial of modified FOLFOX6 as first-line therapy for XXXX of an unknown primary site.

@entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']
@entity420 :: (MESH:D000230,Disease) :: ['adenocarcinoma']
